Jesper Brandgaard/LinkedIn
Dec 7, 2025, 05:45
Jesper Brandgaard: Novo Nordisk Haemophilia Foundation is Evolving into the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Jesper Brandgaard, Chairman at LEO Pharma, posted on LinkedIn:
“As the former President of the Council, I am absolutely delighted to share that the Novo Nordisk Haemophilia Foundation is evolving into the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation. It’s truly inspiring to witness the mission grow to support even more lives. A huge thank you to the Novo Nordisk Foundation for joining as an accelerating partner on this ambitious journey to quadruple the annual beneficiaries by 2030.
Congratulations to the entire NNHF Council and Team – here’s to an exciting new era ahead!”
Get the latest with Hemostasis Today.
-
Mar 7, 2026, 14:42Megan Adediran: When Should Heavy Bleeding Stop Being Called Normal?
-
Mar 7, 2026, 14:41Heghine Khachatryan: Best-Practice Recommendations for Implementing Shared Decision-Making in Hemophilia Care
-
Mar 7, 2026, 14:37Julie Kennedy Lesch: Driving Progress for People Living with Sickle Cell Disease
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Adrian Gottschlich: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease